SP
CMPX icon

SmartHarvest Portfolios’s Compass Therapeutics CMPX Stock Holding History

SmartHarvest Portfolios’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$189K Buy
86,508
+51,795
+149% +$153K 0.06% 378
2026
Q1 		$184K Sell
34,713
-2
-0% -$12 0.08% 316
2025
Q4 		$186K Buy
+34,715
New +$160K 0.06% 317

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SmartHarvest Portfolios's CMPX Position: Q2 2026 in Review

SmartHarvest Portfolios increased its Compass Therapeutics (CMPX) stake by 149% in Q2 2026, buying an estimated $153K and bringing the position to 86,508 shares worth $189K. The position accounts for 0.06% of the portfolio, ranked #378.

SmartHarvest Portfolios first reported a position in CMPX in Q4 2025 and has held it in 3 quarters since. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • SmartHarvest Portfolios held 86,508 shares of Compass Therapeutics worth $189K as of Q2 2026.
  • SmartHarvest Portfolios bought 51,795 Compass Therapeutics shares in Q2 2026, an estimated $153K.
  • Compass Therapeutics made up 0.06% of SmartHarvest Portfolios's portfolio in Q2 2026, its #378 holding.
  • SmartHarvest Portfolios first reported a position in Compass Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on SmartHarvest Portfolios's 13F filing for Q2 2026, filed 4 Aug 2026.